As shown in Figures 6a–d, treatment of Cx26-overexpressing HCC827 and PC9 cells with a specific PI3K/Akt pathway inhibitor LY294002 (25 μM) for 24 h could apparently antagonize the facilitating effects of Cx26 on EMT and gefitinib resistance of NSCLC cells. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.